Xenetic Biosciences, Inc.

NASDAQ: XBIOHealthcare / Biotechnology / USA
0.5900-0.0400-6.35%Vol 298 0131Y Perf -64.40%
Jun 14th, 2019 15:59
BID0.5900 ASK0.6300
Open0.6100 Previous Close0.6300
Pre-Market- After-Trading-
 - -%  - -%
Target Price
10.00 
Analyst Rating
— 0.00
Potencial %
1 594.92 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
★★ —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
★★★ —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)6 
Earnings Rating
Neutral
Price Range Ratio 52wk %
0.24 
Earnings Date
9th Aug 2019

Today's Price Range

0.57000.6200

52wk Range

0.57008.95

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Month
-51.24%
3 Months
-73.06%
6 Months
-77.04%
1 Year
-64.40%
3 Years
-89.27%
5 Years
-97.29%

Name / TickerPriceChg.Chg.%
XBIO0.5900-0.0400-6.35
AAPL192.74-1.4100-0.73
GOOG1 085.35-3.4200-0.31
MSFT132.450.13000.10
XOM74.35-0.3300-0.44
WFC45.590.30000.66
JNJ140.09-0.6200-0.44
FB181.333.86002.18
GE10.23-0.0800-0.78
JPM109.820.28000.26
Earnings HistoryEstimateReportedSurprise %
Q03 2017--0.26-
Q02 2017--0.34-
Q01 2017--0.34-
Q04 2016--0.28-
Q02 2016--5.55-
Q01 2016--0.66-
----
----
Earnings Per EndEstimateRevision %Trend
12/2017 FY-0.890.00-
12/2018 FY-1.150.00-
----
----
Next Report Date9th Aug 2019
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume298 013
Shares Outstanding (in ths.)10 444
Trades Count454
Dollar Volume172 254
Avg. Volume95 567
Avg. Weekly Volume488 561
Avg. Monthly Volume215 700
Avg. Quarterly Volume116 206
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Rating--Strong Buy
1.00

Xenetic Biosciences, Inc.

Xenetic Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. Further, company's proprietary drug development platform, PolyXen, enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company has ongoing business development activities to explore partnerships utilizing its PolyXen delivery platform.

CEO: Jeffrey F. Eisenberg

Teplephone: +1 781 778-7720

Address: 40 Speen Street, Framingham 01701, MA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

54%46%

Bearish Bullish

74%26%

News